Evaluation of efficacy and safety of a herbal medicine used for the treatment of malaria.
Resistance of Plasmodium falciparum to chloroquine has been reported in several countries. Other anti-malarial drugs in use are expensive and not readily accessible to most people in malaria endemic countries. This has led to renewed interest in the development of herbal medicines that have the potential to treat malaria with little or no side effects. This study obtained a preliminary information on the safety and effectiveness of a plant decoction (AM-1), used in treating malaria. The AM-1 is formulated from Jatropha curcas, Gossypium hirsutum, Physalis angulata and Delonix regia. Patients with suspected malaria attending a herbal clinic were enrolled in the study on voluntary basis. They were hospitalized for treatment, clinical observation, biochemical and haematological monitoring, and parasite clearance while on AM-1. In addition male and female Sprague Dawley rats were used to evaluate the acute and subchronic toxicity effects of AM-1. The AM-1 eliminated malaria parasites (Plasmodium falciparum and Plasmodium malarie) from the peripheral blood of patients with malaria. In addition the AM-1 did not show any undesired effects in the patients as well as in laboratory rats. The AM-1, however, showed differential effect on the activities of selected cytochrome P450 isozymes (7-pentoxyresorufin-O-depentylation, 7-ethoxyresorufin-O-deethylation and p-nitrophenol hydroxylase) in relation to sex of the laboratory rats. These results indicate that AM-1 could be used to treat malaria. However, it could precipitate interactions with other drugs via their biotransformation and elimination. The obtained data warrant further studies in a large number of malaria subjects with monitoring for possible drug interactions.
Ankrah
Nii-Ayi
NA
Noguchi Memorial Institute for Medical Research, Legon, Gana. nankrah@noguchi.mimcom.net
Nyarko
Alexander K
AK
Addo
Phyllis G A
PG
Ofosuhene
Mark
M
Dzokoto
Comfort
C
Marley
Ethel
E
Addae
Michael M
MM
Ekuban
Frederick A
FA
D000293:Adolescent; D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D004347:Drug Interactions; D007887:Fabaceae; D005260:Female; D003368:Gossypium; D006801:Humans; D031286:Jatropha; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008288:Malaria / Q000188:drug therapy*; D008297:Male; D032321:Physalis; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D010946:Plants, Medicinal; D010963:Plasmodium falciparum / Q000187:drug effects; D010965:Plasmodium malariae / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley
D000962:Antimalarials; D010936:Plant Extracts; D003577:Cytochrome P-450 Enzyme System